Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, a global leader in consumer health, covers the month of September 2025. The report specifically details a transaction in own shares executed on September 18, 2025, and announced on September 19, 2025.
Key Financial Metrics and Transaction Details
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on a share buyback transaction under the second tranche of a programme announced on July 31, 2025.
- Total Shares Purchased: 4,314,000 ordinary shares of £0.01 each.
- Transaction Venues: London Stock Exchange (CBOE UK/BXE and CBOE UK/CXE).
- Price Range: Highest price paid was 344.45 pence; lowest price paid was 340.20 pence.
- Volume Weighted Average Price (VWAP): 341.8544 pence (LSE) and 341.2133 pence (CBOE).
- Treasury Shares: Following settlement, 18,887,545 shares are held as treasury shares.
- Voting Rights: 8,933,466,103 ordinary shares with voting rights remain outstanding.
Material Changes
The primary material change is the reduction of outstanding shares with voting rights due to the repurchase of 4,314,000 shares. The filing does not disclose changes in operational performance or financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It is a routine disclosure of a capital allocation activity. The purchased shares are intended to be held as treasury shares.
Investor Verification Checklist
- Verify the total number of treasury shares held (18,887,545) against the company's latest capital structure filings.
- Confirm the remaining number of shares with voting rights (8,933,466,103) for disclosure threshold calculations under FCA rules.
- Review the full trade breakdown available via the provided London Stock Exchange link for granular execution details.
- Check the status of the remaining buyback programme announced on July 31, 2025, to understand future capital return potential.